Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is pioneering the use of epigenetics to evaluate heart disease risk, moving beyond traditional genetic testing to consider how lifestyle, behavior, and environment influence gene expression. The company's diagnostic platform examines epigenetic markers—chemical modifications that turn genes on or off without altering the DNA sequence—to provide a more comprehensive risk assessment.
Epigenetics represents a paradigm shift in cardiovascular diagnostics. While family history and genetic mutations are known risk factors, they account for only a fraction of heart disease cases. Epigenetic changes, influenced by diet, exercise, stress, and exposure to toxins, can accumulate over time and contribute to disease development. By analyzing these modifications, Cardio Diagnostics aims to identify individuals at risk who might otherwise be overlooked by standard screening methods.
CEO of Cardio Diagnostics emphasized that epigenetics not only identifies problems but also offers potential solutions. Unlike fixed genetic mutations, epigenetic changes are potentially reversible, meaning that lifestyle interventions could modify risk. This aspect makes epigenetic testing particularly valuable for personalized prevention strategies.
The company's approach aligns with growing research highlighting the importance of epigenetic factors in cardiovascular health. Studies have shown that epigenetic signatures can predict heart attack and stroke risk more accurately than traditional risk factors alone. Cardio Diagnostics' tests are designed to detect these signatures and provide actionable insights for patients and clinicians.
For investors, Cardio Diagnostics represents a novel entry in the burgeoning field of epigenetic diagnostics. The company's technology could tap into a large market of individuals seeking more precise health assessments. However, the field is still evolving, and widespread clinical adoption will require validation through further studies and regulatory approvals.
More information about Cardio Diagnostics and its epigenetic testing can be found in the company's newsroom at https://ibn.fm/CDIO.
